Patent application number | Description | Published |
20090226446 | Method to Inhibit the Propagation of an Undesired Cell Population - Disclosed is a method for inhibiting the propagation of an undesired cell population, the method comprising introducing into a cell an antagonist of Bat 3, or of a functional variant thereof, said antagonist depleting Bat 3, a functional variant thereof, in a cell of said cell population, and verifying the reduced proliferation and/or cell death in Bat 3 depleted cell populations; disclosed is further the use of a Bat 3 antagonist for the manufacture of a medicament for the treatment of diseases which are caused by the propagation of an undesired cell population. | 09-10-2009 |
20100029751 | COMPOSITIONS COMPRISING A PARVOVIRUS VP1-VARIANT AND A PARVOVIRUS NS1 PROTEIN FOR INDUCTION OF CYTOLYSIS - The present invention provides a composition comprising (a) a parvovirus NS1 protein and (b) a parvovirus VP1 protein. Furthermore, the present invention provides DNA sequences encoding said proteins. The composition of the invention is useful for the preparation of a toxin for treating tumoral diseases. | 02-04-2010 |
20100144847 | FUSION POLYPEPTIDE SUITABLE AS A CYTOTOXIN - The present invention relates to fusion polypeptides including (a) a binding site for a cytoskeleton component and (b | 06-10-2010 |
20110020287 | Parvovirus Cancer Therapy and Combination with Chemotherapy - Described is a pharmaceutical composition containing (a) a parvovirus and (b) a chemotherapeutic agent, preferably as separate entities. The parvovirus might be based on parvovirus H1, LuIII, Mouse minute virus (MMV), Mouse parvovirus (MPV), Rat minute virus (RMV), Rat parvovirus (RPV), Rat virus (RV), vectors based on the foregoing viral species, and/or cells capable of actively producing the foregoing viral species. The pharmaceutical composition is beneficial for the treatment of a tumor. Tumors for which a parvovirus or the adjunction of the invention has particular utility include glioma, medulloblastoma, meningioma and pancreatic cancer. Preferred chemotherapeutic agents are gemcitabine and Temozolodine. | 01-27-2011 |
20110033425 | Parvovirus Having a CPG-Enriched Genome Useful for Cancer Therapy - A parvovirus characterized by a CpG-enriched genome, wherein the genome contains at least 2 additional CpG inserts that are not present in the wild type genome is described as well as the use of said parvovirus, e.g., a parvovirus based on parvovirus H1, LuIII, Mouse minute virus (MMV), Mouse parvovirus (MPV), Rat minute virus (RMV), Rat parvovirus (RPV), Rat virus (RV), vectors based on the foregoing viral species, and/or cells capable of actively producing the foregoing viral species for the preparation of a pharmaceutical composition, e.g., for the treatment of cancer, preferably pancreas carcinoma, hepatoma or lymphoma. | 02-10-2011 |
20120213734 | Method for Cancer Therapy Based on a Co-Administration of a Parvovirus and a Cytokine - Described is a pharmaceutical composition comprising (a) a parvovirus and (b) a cytokine, preferably IFN-γ, and the use of said composition for treatment of cancer, e.g., a brain tumor. | 08-23-2012 |
20120237483 | Oncolytic Virotherapy for Prevention of Tumor Recurrence - Described is a parvovirus for preventing recurrence of a tumor, preferably a malignant brain tumor or pancreas tumor. | 09-20-2012 |
20130028913 | ANTIBODY THAT BINDS TO H-1 PARVOVIRUS - Described is an antibody or an antigen binding fragment thereof specifically binding to a full or empty H-1 parvovirus capsid. Such an antibody is useful for various diagnostic and therapeutic methods, e.g., for the detection/therapy of an H-1 parvovirus infection during pregnancy since parvovirus affects about 1 in 400 pregnancies and may cause fetal loss or fetal hydrops. | 01-31-2013 |
20130058899 | Cancer Therapy with a Parvovirus Combined with an HDAC Inhibitor - Described is a pharmaceutical composition comprising (a) a parvovirus and (b) a histone deacetylase inhibitor (HDACI) and the use of said composition for treatment of cancer, e.g., brain tumor, cervical carcinoma, or pancreatic carcinoma. | 03-07-2013 |
20130089523 | ADENOVIRUS DERIVED HELPER VIRUS FOR ENHANCING RECOMBINANT PARVOVIRUS PRODUCTION - Described is an adenovirus derived helper virus which may comprise the adenoviral DNA sequences for E2a, S4 (orf6), the VA1 RNA gene, and the parvovirus VP capsid gene unit. Also described is a method of efficiently preparing a recombinant parvovirus (particle) which is based on the use of various adenoviral derived helper viruses/vectors. | 04-11-2013 |
20130101989 | Diagnostic Method for Predicting the Response of a Patient to Chemovirotherapy or Radiovirotherapy - Described is a diagnostic method for predicting the response of a patient to chemovirotherapy or radiovirotherapy, comprising exposing primary tumor cells from a patient, e.g., tumor cells obtained from a brain tumor or pancreatic cancer, to (i) a parvovirus and/or (ii) a chemotherapeutic agent or radiotherapy, and determining the reduction of the expression or concentration of ISG15. | 04-25-2013 |
20130129678 | CO-ADMINISTRATION OF A PARVOVIRUS AND A CYTOKINE FOR THERAPY OF PANCREATIC CANCER - The application relates to a combination of a parvovirus and a cytokine, preferably IFNγ, for use in treating pancreatic cancer (PDAC), in particular a terminal stage of this disease. | 05-23-2013 |
20130129683 | Modified Rodent Parvovirus Capable of Propagating and Spreading Through Human Gliomas - Described are (a) parvovirus variants capable of propagating and spreading through human tumor cells which is obtainable by serially passaging a rodent parvovirus as starting strain in semi-permissive human tumor cells, and (b) parvovirus variants capable of propagating and spreading through human tumor cells characterized by particular amino acid deletions and/or substitutions, e.g. a deletion of several amino acids in the C-terminus of NS1/middle exon of NS2. A pharmaceutical composition containing such parvoviruses as well as their use for the treatment of cancer, preferably a glioblastoma, is also described. | 05-23-2013 |
20130189265 | MODIFIED PARVOVIRUS HAVING ENHANCED ANTI-TUMOR EFFICACY - Described are parvovirus variants derived, e.g., from H-1PV, showing higher anti-tumor potential compared to the wild type parvovirus, wherein said variant is characterized by (a) an amino acid substitution, alteration or addition, preferably substitution at position Lys96 of NS-2 and/or position Leu103 of NS-2 (together with a amino acid substituion at position Tyr595 of NS-1 in the latter case), or (b) an in-frame deletion in the parvovirus genome, preferably a deletion resulting in a large amino acid deletion in both the central part (aa 96-133) of NS-2 and the C-terminal part (aa 587-624) of NS-1. The present invention also relates to the use of said parvovirus variants for cancer therapy. | 07-25-2013 |
20130209413 | USE OF PARVOVIRUS FOR ELIMINATING CANCER STEM CELLS (CSCs) - Described is the use of a parvovirus, preferably H-1PV, for the therapeutical elimination of cancer stem cells (CSCs), preferably neuroblastoma stem cells and glioblastoma stem cells. | 08-15-2013 |
20130224154 | RETARGETING OF RAT PARVOVIRUS H-1PV TO CANCER CELLS THROUGH GENETIC ENGINEERING OF ITS CAPSID - Described is a parvovirus, in particular a H-IPV, that can be genetically retargeted through modification of its capsid, which is useful in cancer therapy. | 08-29-2013 |
20130344034 | Parovirus Having a CpG-Enriched Genome Useful for Cancer Therapy - A parvovirus characterized by a CpG-enriched genome, wherein the genome contains at least 2 additional CpG inserts that are not present in the wild type genome is described as well as the use of said parvovirus, e.g., a parvovirus based on parvovirus H1, LuIII, Mouse minute virus (MMV), Mouse parvovirus (MPV), Rat minute virus (RMV), Rat parvovirus (RPV), Rat virus (RV), vectors based on the foregoing viral species, and/or cells capable of actively producing the foregoing viral species for the preparation of a pharmaceutical composition, e.g., for the treatment of cancer, preferably pancreas carcinoma, hepatoma or lymphoma. | 12-26-2013 |
20140205573 | ONCOLYTIC VIROTHERAPY FOR THE THERAPY OF SARCOMA - The present invention relates to a parvovirus for the treatment of mesenchymal tumors, preferably malignant bone tumors such as localized and metastasized bone tumors, in particular osteosarcoma and Ewing's sarcoma. A preferred parvovirus includes a replication competent parvovirus H-1PV. | 07-24-2014 |
20140234261 | Parvovirus Cancer Therapy and Combination with Chemotherapy - Described is a pharmaceutical composition containing (a) a parvovirus and (b) a chemotherapeutic agent, preferably as separate entities. The parvovirus might be based on parvovirus H1, LuIII, Mouse minute virus (MMV), Mouse parvovirus (MPV), Rat minute virus (RMV), Rat parvovirus (RPV), Rat virus (RV), vectors based on the foregoing viral species, and/or cells capable of actively producing the foregoing viral species. The pharmaceutical composition is beneficial for the treatment of a tumor. Tumors for which a parvovirus or the adjunction of the invention has particular utility include glioma, medulloblastoma, meningioma and pancreatic cancer. Preferred chemotherapeutic agents are gemcitabine and Temozolodine. | 08-21-2014 |
20140235699 | ADENO-PARVOVIRUS CHIMERA WITH ENHANCED ONCOLYTICAL POTENTIAL - Described is a chimerical adenovirus-parvovirus vector characterized in that it comprises the entire parvovirus genome inserted into a adenovirus genome, wherein: (a) the adenovirus genome is characterized by deletion of E1 and E3, and (b) the biological activity of the parvoviral protein NS, preferably NS1, is reduced or eliminated. | 08-21-2014 |
20140310829 | MODIFIED PARVOVIRUS USEFUL FOR GENE SILENCING - Described are methods for efficiently down regulating the expression of a gene of interest in a cell by use of a modified rodent parvovirus that contains an expressible target specific nucleic acid, preferably an shRNA expression cassette. Also described are cells or organisms comprising said parvovirus. | 10-16-2014 |
20140328798 | Co-Administration of a Parvovirus and a Cytokine for Therapy of Pancreatic Cancer - The present invention relates to a combination of a parvovirus and a cytokine, preferably IFNγ, for use in treating pancreatic cancer, in particular a terminal stage of this disease. | 11-06-2014 |
20150030567 | Cancer Therapy with a Parvovirus Combined with an HDAC Inhibitor - Described is a pharmaceutical composition comprising (a) a parvovirus and (b) a histone deacetylase inhibitor (HDACI) and the use of said composition for treatment of cancer, e.g., brain tumor, cervical carcinoma, or pancreatic carcinoma. | 01-29-2015 |